title: Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes.
abstract: Diabetes mellitus-related cardiomyopathy (DMCMP) was originally described as a dilated phenotype with eccentric left ventricular (LV) remodelling and systolic LV dysfunction. Recently however, clinical studies on DMCMP mainly describe a restrictive phenotype with concentric LV remodelling and diastolic LV dysfunction. Both phenotypes are not successive stages of DMCMP but evolve independently to respectively heart failure with preserved left ventricular ejection fraction (HFPEF) or reduced left ventricular ejection fraction (HFREF). Phenotype-specific pathophysiological mechanisms were recently proposed for LV remodelling and dysfunction in HFPEF and HFREF consisting of coronary microvascular endothelial dysfunction in HFPEF and cardiomyocyte cell death in HFREF. A similar preferential involvement of endothelial or cardiomyocyte cell compartments explains DMCMP development into distinct restrictive/HFPEF or dilated/HFREF phenotypes. Diabetes mellitus (DM)-related metabolic derangements such as hyperglycaemia, lipotoxicity, and hyperinsulinaemia favour development of DMCMP with restrictive/HFPEF phenotype, which is more prevalent in obese type 2 DM patients. In contrast, autoimmunity predisposes to a dilated/HFREF phenotype, which manifests itself more in autoimmune-prone type 1 DM patients. Finally, coronary microvascular rarefaction and advanced glycation end-products deposition are relevant to both phenotypes. Diagnosis of DMCMP requires impaired glucose metabolism and exclusion of coronary, valvular, hypertensive, or congenital heart disease and of viral, toxic, familial, or infiltrative cardiomyopathy. In addition, diagnosis of DMCMP with restrictive/HFPEF phenotype requires normal systolic LV function and diastolic LV dysfunction, whereas diagnosis of DMCMP with dilated/HFREF phenotype requires systolic LV dysfunction. Treatment of DMCMP with restrictive/HFPEF phenotype is limited to diuretics and lifestyle modification, whereas DMCMP with dilated/HFREF phenotype is treated in accordance to HF guidelines.
authors.affiliation: University Medical Center, Belgrade, Serbia.
authors.forename: Petar M
authors.initials: PM
authors.lastname: Seferović
authors.affiliation: Institute for Cardiovascular Research VU (ICaR-VU), VU University Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands wj.paulus@vumc.nl.
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Paulus
mesh_terms: D015551:Autoimmunity / Q000502:physiology; D002311:Cardiomyopathy, Dilated / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D002313:Cardiomyopathy, Restrictive / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D058065:Diabetic Cardiomyopathies / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006333:Heart Failure / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology; D010641:Phenotype; D040242:Risk Reduction Behavior; D018754:Ventricular Dysfunction / Q000175:diagnosis / Q000209:etiology / Q000628:therapy
chemical_list: D017127:Glycation End Products, Advanced; D007004:Hypoglycemic Agents
keywords: Diabetes mellitus; Diabetic cardiomyopathy; Diastolic dysfunction; Heart failure; Left ventricular Remodelling